PriceTargets.com logo

C4X Discovery - C4XD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 12 As of 04/25/2024 01:00 AM ET
▲ +2.57 (27.25%)

This chart shows the closing price for C4XD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New C4X Discovery Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for C4XD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for C4XD

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for C4X Discovery in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 12.

This chart shows the closing price for C4XD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in C4X Discovery. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/14/2023Shore CapitalReiterated RatingBuy
8/17/2023Shore CapitalReiterated RatingBuy
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
C4X Discovery logo
C4X Discovery Holdings plc operates as drug discovery company in the United Kingdom. The company provides Taxonomy3, a novel in silico platform technology that utilizes proprietary mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behavior and physical properties of drug molecules; and 4Sight for visualizing 4D molecules in virtual reality research scientists to view, understand and interrogate the complex, multidimensional molecular shape data of drug molecules. Its product pipeline includes Orexin-1, a receptor antagonist for the treatment of addictive disorders; NRF-2 activator to treat various inflammatory diseases; IL-17A inhibitor for inflammation diseases; a4ß7 integrin inhibitors for the treatment of inflammatory bowel disease; and MALT-1 inhibitors to treat hematological cancer. The company was formerly known as Schosween 24 plc and changed its name to C4X Discovery Holdings plc October 2014. C4X Discovery Holdings plc was incorporated in 2007 and is based in Manchester, the United Kingdom.
Read More

Today's Range

Now: GBX 12
Low: 8.30
High: 12

50 Day Range

MA: GBX 11.03
Low: 7.35
High: 14.85

52 Week Range

Now: GBX 12
Low: 7
High: 22

Volume

3,769,955 shs

Average Volume

1,220,396 shs

Market Capitalization

£30.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27

Frequently Asked Questions

What sell-side analysts currently cover shares of C4X Discovery?

The following sell-side analysts have issued stock ratings on C4X Discovery in the last year: Shore Capital.
View the latest analyst ratings for C4XD.

What is the current price target for C4X Discovery?

0 Wall Street analysts have set twelve-month price targets for C4X Discovery in the last year. has the lowest price target set, forecasting a price of £100,000 for C4X Discovery in the next year.
View the latest price targets for C4XD.

What is the current consensus analyst rating for C4X Discovery?

C4X Discovery currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe C4XD will outperform the market and that investors should add to their positions of C4X Discovery.
View the latest ratings for C4XD.

What other companies compete with C4X Discovery?

Other companies that are similar to C4X Discovery include Sareum, Hemogenyx Pharmaceuticals, OKYO Pharma, Destiny Pharma and AorTech International. Learn More about companies similar to C4X Discovery.

How do I contact C4X Discovery's investor relations team?

C4X Discovery's physical mailing address is 53 Portland Street, MANCHESTER, M1 3LD, United Kingdom. The company's listed phone number is +44-161-2355085. The official website for C4X Discovery is www.c4xdiscovery.com. Learn More about contacing C4X Discovery investor relations.